34 Series B biotech investors in the US
We list 34 Series B biotech investors in the US as of November 2026: each has an SEC filing on file, and the list was last checked on 6 Nov 2026. The cities with the most head offices on this list are New York (5), Seattle (2) and San Francisco (2).
Top 5 Series B biotech investors in the US, ranked by recent fund activity
Among firms with a published profile and a dated fund or deal in the last 24 months. The rule: Activity score out of 100: recency of the latest fund filing or dated deal (30: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (20; half of that when the sector is stated only), stage focus (15: all of it when Series B is the only stage the firm states, split evenly when it states more), stated focus on the US (15: full marks when the firm names the US as where it invests, half when it says global), size of the fund on file on a log scale (12) and completeness of the public record (8). Stage and regional focus are our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns. The same rule orders the whole list; it is repeated in the method box.
Madrona
Type: VC firm · HQ: Seattle, WA · Stages: Pre-seed, Seed, Series A, Series B, Growth · Focus: Biotech, AI, Consumer, Deep Tech · Latest activity: New deal, Oct 2026 · Fund size on file: $490M (SEC Form D, 2025)
Dated new deal in Oct 2026; $490M fund on file (SEC Form D, 2025); states biotech and life sciences as a focus; backs pre-seed, seed, Series A; names the US as where it invests; 8 named decision-makers on file.
Bison Ventures
Type: VC firm · HQ: San Francisco, CA · Stages: Pre-seed, Seed, Series A, Series B · Focus: Biotech, AI, Healthtech, Energy · Latest activity: New fund, Oct 2026 · Fund size on file: $160M (SEC Form D, 2025)
Latest fund filing dated Oct 2026; $160M fund on file (SEC Form D, 2025); 21% of its observed portfolio is biotech and life sciences; backs pre-seed, seed, Series A; names the US as where it invests; 2 named decision-makers on file.
How Women Invest
Type: VC firm · HQ: Oakland, CA · Stages: Pre-seed, Seed, Series A, Series B · Focus: Biotech, Healthtech, AI, B2B · Latest activity: New fund, Sep 2026 · Fund size on file: $12M (SEC Form D, 2026)
Latest fund filing dated Sep 2026; $12M fund on file (SEC Form D, 2026); 19% of its observed portfolio is biotech and life sciences; backs pre-seed, seed, Series A; names the US as where it invests; 8 named decision-makers on file.
Arboretum Ventures
Type: VC firm · HQ: Ann Arbor, MI · Stages: Series A, Series B · Focus: Biotech, Healthtech, Medtech · Latest activity: Portfolio news, Mar 2026 · Fund size on file: $250M (SEC Form D, 2022)
Portfolio news dated Mar 2026; $250M fund on file (SEC Form D, 2022); 35% of its observed portfolio is biotech and life sciences; backs Series A, Series B; names the US as where it invests; 7 named decision-makers on file.
Andreessen Horowitz (a16z)
Type: VC firm · HQ: Menlo Park, CA · Stages: Seed, Series A, Series B, Growth · Focus: Biotech, AI, Defense Tech, Healthtech · Latest activity: New fund, Aug 2026
Latest fund filing dated Aug 2026; states biotech and life sciences as a focus; backs seed, Series A, Series B; names the US as where it invests; 2 named decision-makers on file.
First 17 of 34 Series B biotech investors in the US
| Investor | Type | HQ | Stagesour research | Focusour research | Latest fund or deal | Fund sizeas filed or stated | Checked | Contacts |
|---|---|---|---|---|---|---|---|---|
| Madrona | VC firm | Seattle, WA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Consumer, Deep Tech | New deal, Oct 2026 | $490M (SEC Form D, 2025) | 5 Nov 2026 | 8 names · Unlock |
| Bison Ventures | VC firm | San Francisco, CA | Pre-seed, Seed, Series A, Series B | Biotech, AI, Healthtech, Energy | New fund, Oct 2026 | $160M (SEC Form D, 2025) | 4 Nov 2026 | 2 names, firm email · Unlock |
| How Women Invest | VC firm | Oakland, CA | Pre-seed, Seed, Series A, Series B | Biotech, Healthtech, AI, B2B | New fund, Sep 2026 | $12M (SEC Form D, 2026) | 4 Nov 2026 | 8 names · Unlock |
| Arboretum Ventures | VC firm | Ann Arbor, MI | Series A, Series B | Biotech, Healthtech, Medtech | Portfolio news, Mar 2026 | $250M (SEC Form D, 2022) | 5 Nov 2026 | 7 names · Unlock |
| Andreessen Horowitz (a16z) | VC firm | Menlo Park, CA | Seed, Series A, Series B, Growth | Biotech, AI, Defense Tech, Healthtech | New fund, Aug 2026 | 4 Nov 2026 | 2 names · Unlock | |
| Cornucopian Capital | VC firm | Montclair, NJ | Pre-seed, Seed, Series A, Series B | Biotech, Healthtech, AI, Medtech | New fund, Aug 2026 | $12M (SEC Form D, 2024) | 4 Nov 2026 | 1 name · Unlock |
| Calculus VC | VC firm | Foster City, CA | Series A, Series B | Biotech, AI, Deep Tech, Healthtech | New deal, Aug 2026 | $1M (SEC Form D, 2025) | 4 Nov 2026 | 1 name, firm email · Unlock |
| B Capital | VC firm | Manhattan Beach, CA | Seed, Series A, Series B, Growth | Biotech, AI, Fintech, Healthtech | New fund, Jul 2025 | $307M (SEC Form D, 2023) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Cultivation Capital | VC firm | St. Louis, MO | Seed, Series A, Series B | Biotech, Healthtech, SaaS, Agritech | New fund, Sep 2026 | $100M (SEC Form D, 2022) | 4 Nov 2026 | 8 names · Unlock |
| Antler | Accelerator | New York, NY | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Healthtech, Consumer | New deal, Aug 2026 | $90M (SEC Form D, 2023) | 4 Nov 2026 | 8 names · Unlock |
| Overlap Holdings | VC firm | Hicksville, NY | Seed, Series A, Series B | Biotech, AI, Energy, Climate Tech | New fund, Oct 2026 | $16M (SEC Form D, 2023) | 4 Nov 2026 | 8 names · Unlock |
| Cerberus Ventures | VC firm | New York, NY | Pre-seed, Seed, Series A, Series B | Biotech, AI, Industrial Tech, Quantum | New fund, Jun 2026 | $75M (SEC Form D, 2024) | 4 Nov 2026 | 8 names · Unlock |
| Apple Tree Venture | VC firm | New York, NY | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech | Portfolio news, Sep 2025 | $3.5B (SEC Form ADV) | 5 Nov 2026 | 8 names, firm email · Unlock |
| Awareness Venture | VC firm | Westport, MA | Seed, Series A, Series B | Biotech, Healthtech, AI, Medtech | New fund, Nov 2024 | $6M (SEC Form D, 2023) | 5 Nov 2026 | 3 names · Unlock |
| Frazier Life Sciences | VC firm | Palo Alto, CA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech | New fund, Mar 2025 | $7.0B (SEC Form ADV) | 5 Nov 2026 | 6 names · Unlock |
| Bramalea Partners | VC firm | Medfield, MA | Series B, Growth | Biotech, Healthtech, AI, Fintech | Portfolio news, Mar 2026 | $78M (SEC Form D, 2021) | 5 Nov 2026 | 2 names · Unlock |
| Star51 Capital | VC firm | New York, NY | Seed, Series A, Series B, Growth | Biotech, Healthtech, AI, Robotics | New deal, Sep 2026 | 4 Nov 2026 | 3 names, firm email · Unlock |
You are seeing 17 of 34. The full list adds 17 more investors and 191 named decision-makers.
One-time payment. No subscription. No account.
Or get the free sample.
How these 34 break down
By US state
| US state | On this list | Share |
|---|---|---|
| California | 11 | 32% |
| New York | 7 | 21% |
| Massachusetts | 3 | 9% |
| Washington | 2 | 6% |
| Michigan | 2 | 6% |
| New Jersey | 2 | 6% |
By type
| Type | On this list | Share |
|---|---|---|
| VC firm | 32 | 94% |
| Accelerator | 1 | 3% |
| Government or university fund | 1 | 3% |
Method and limits
- Source
- All 34 rows carry an SEC filing (Form D or Form ADV). All 34 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule
- Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at Series B.
- Order
- Firms with a published profile come first. Activity score out of 100: recency of the latest fund filing or dated deal (30: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (20; half of that when the sector is stated only), stage focus (15: all of it when Series B is the only stage the firm states, split evenly when it states more), stated focus on the US (15: full marks when the firm names the US as where it invests, half when it says global), size of the fund on file on a log scale (12) and completeness of the public record (8). Stage and regional focus are our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Last refreshed
- November 2026. Rows on this list were checked between 4 Nov 2026 and 6 Nov 2026.
- Fill rates
- Of 34 rows: stage 34, sector 34, fund size 29, website 34. In the paid file: named decision-makers on 33 rows, firm email on 12, LinkedIn page on 19, check size on 4.
- Corrections
- Email hello@theinvestordatabase.com or use the update form. We act within 5 working days.
Questions
How many Series B biotech investors in the US are there?
We list 34 as of November 2026. 19 of the 34 have a fund filing or a dated deal in the last 12 months. The cities with the most are New York (5), Seattle (2) and San Francisco (2).
Which Series B biotech investors in the US raised a new fund in the last 12 months?
13 of the 34 have a fund filing dated in the last 12 months. The most recent on this list are Bison Ventures (Oct 2026), Overlap Holdings (Oct 2026) and Cultivation Capital (Sep 2026).
What is the typical fund size of Series B biotech investors in the US?
The median fund size on file for this list is $75M, across the 21 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 13 do not disclose a size there.
How do I contact Series B biotech investors in the US?
The paid file holds 191 named decision-makers across 33 of these 34 and a firm email for 12. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.
Where does the data on Series B biotech investors in the US come from?
All 34 rows have an SEC filing on file (Form D or Form ADV). Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 6 Nov 2026 at the latest. The whole file is re-verified twice a year.
Broader lists
Biotech venture capital firms in the US (297)Series B investors in the US (165)Series B biotech investors (73)
Related lists
Seed biotech investors in the US (159)Series B AI investors in the US (126)Series B SaaS investors in the US (108)Pre-seed biotech investors in the US (81)Series B healthtech investors in the US (69)Series A biotech investors in the US (59)Series B fintech investors in the US (59)Growth-stage biotech investors in the US (44)Series B deep tech investors in the US (41)Series B cybersecurity investors in the US (37)Series B medtech investors in the US (36)Series B energy investors in the US (29)Series B industrial tech investors in the US (29)Series B consumer investors in the US (29)Series B hardware investors in the US (28)Series B B2B investors in the US (27)Series B climate tech investors in the US (27)Series B developer tools investors in the US (21)
Not sure this is the right list? Describe your raise in the investor matching tool and get a shortlist. The link opens it set to biotech and life sciences, Series B and the US. Guide: how many investors to pitch. Markdown version of this page.
Check the quality first
A free sample of 100 investors, every column, with sources and dates.